fbpx Skip to main content
 

Search

Janssen Search

Search results

762 SEARCH RESULTS FOR

research-development

Not finding what you're looking for? Visit Janssen in your country.
PAGE 56 OF 77

Pages

May 31, 2024 Investigational chemotherapy-free regimen of RYBREVANT® plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease Landmark Phase 3 MARIPOSA data featured in an oral presentation at ASCO ...

DAN PETTITT VICE PRESIDENT MARKET ACCESS, IMMUNOLOGY Dan Pettitt is Vice President, Market Access, Immunology for the Global Commercial Strategy Organization, Janssen Global Services. He is responsible for developing product access strategies and ...

Jun 03, 2024 88 percent of transplant-eligible patients achieved a complete response or better, and 47 percent of patients sustained MRD-negativity for longer than one year with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based induction, ...

Sep 14, 2024 Spain Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease New results show potential of RYBREVANT ® beyond lung cancer BARCELONA, September 14, 2024 – Johnson & Johnson ...

Article Type:  Oncology Establishing and Capturing Value Throughout the Product Lifecycle At Janssen, getting our medicines to patients who will benefit is our mission and why we exist. From a market access perspective, this means that, very early in the ...

Article Block Text:  Article Type:  Other Awareness & Advocacy Pulmonary Hypertension Five Things We Know About Pulmonary Arterial Hypertension Pulmonary arterial hypertension (PAH) is a deadly disease, but it can be managed—if you get a timely ...

  Five Things We Know About Pulmonary Arterial Hypertension Pulmonary arterial hypertension (PAH) is a deadly disease, but it can be managed—if you get a timely diagnosis. Here is what the latest science and research has revealed about PAH, including who ...

Igniting Positive Change: A Story for International Women’s Day 2020   I carpool with a colleague, Brenda. She and I work in different areas of R&D, grew up on different continents and have different tastes in food. But, despite our diverse ...

Neuropsychiatric Disorders: Expanding our focus to include the full range of psychosis spectrum disorders and mood dysregulation Janssen's heritage in neuroscience began more than 60 years ago, when our namesake, Dr. Paul Janssen, developed a drug ...

Our Focus on Collaborations and Partnerships We believe that innovation can come from anywhere and is often the result of unified efforts from multiple collaborators. Janssen has a demonstrated appreciation for the value of collaboration and partnership, ...

762 SEARCH RESULTS FOR

research-development

Not finding what you're looking for? Visit Janssen in your country.
PAGE 56 OF 77

Pages